The biopharmaceutical industry is developing rapidly, and the import substitution space of domestic chromatography media is broad

It is reported that at the recent Boston Biotechnology Week, domestic microsphere suppliers appeared with core products, and a total of more than 100 kinds of soft rubber chromatography microspheres were launched, showing potential partners in the biopharmaceutical industry from all over the world the technical advantages and service capabilities
of domestic enterprises in the field of biopharmaceutical raw materials.
Chromatography is the downstream of biopharmaceuticals, in the pharmaceutical production is a very important link, chromatography media has been widely used in
vaccines, recombinant protein drugs, IVD raw materials, CGT, antibody drugs and other fields of separation and purification.
In recent years, under the background of the rapid development of the biopharmaceutical industry, the demand for chromatography media is strong, and the industry has also ushered in rapid development
.
Pharmaceutical industry (Image source: Pharma.
com) According to Frost & Sullivan's statistics, the global biopharmaceutical market size has reached $341.
2 billion in 2021, and it is expected that this market size will grow to $665.
1 billion by 2030, with a CAGR (2022E-2030E) of 7.
6%.

In China, China's biopharmaceutical market reached 464.
4 billion yuan in 2021 and is expected to grow to 1,319.
8 billion yuan by 2030, with a CAGR of 11.
6%
(2022E-2030E).
Biopharmaceutical research in the Asia-Pacific region started late, and downstream separation and purification technology is relatively weak, but with the rapid development of the biopharmaceutical industry in recent years and the expansion of the production capacity of biopharmaceutical CDMO enterprises, the huge R&D and production demand has brought about an increase
in the growth rate of chromatography chemistries.
According to MarketsandMarkets statistics and forecasts, the chromatography packing market size in the Asia-Pacific region was about $500 million in 2019 and is expected to grow to $760 million by 2024, with a CAGR of 9.
39%
(2019E-2024E).
。 From the perspective of industry structure, chromatography packing material because of its high-tech properties, high market concentration, mainly by foreign-funded head enterprises with strong product research and development strength to occupy most of the share, but the price of such imported chromatography media is relatively high, domestic pharmaceutical companies in the trend of centralized procurement price reduction, medical insurance control fee under the pressure of cost reduction and efficiency increase, therefore, domestic chromatography media is expected to embrace the space of import substitution with price advantage and increasing performance, and the market prospects are broad
。 It is reported that under the background of the vigorous development of the biomedical industry and the expansion of the production capacity of pharmaceutical companies, some domestic purification chromatography media companies have seized the opportunity with their own strength and have tasted the "sweetness"
.
For example, Navitas' 2021 annual report shows that during the reporting period, the company's operating income in the biomedical field was 390 million yuan, an increase of 134.
17% over the same period of the previous year, accounting for 87.
43% of the total operating income of the current period, an increase of 6 percentage points over the previous year.
Among them, the sales revenue of chromatography packing materials and chromatography media was about 349 million yuan, accounting for 78.
13% of the total operating income of the current period, an increase of 148.
54%
over the previous year.
In 2021, the company had 500 customers for chromatography packing materials and chromatography media products, an increase of about 101 over the previous year; The sales revenue of chromatography packing materials and chromatography media products used in the formal production or phase III clinical projects of pharmaceutical companies was about 164 million yuan, accounting for 36.
78% of the total operating income of
the current period.
In order to seize a new round of development opportunities, some domestic enterprises are actively developing layout
.
For example, in March 2022, Navitas, a shareholding subsidiary of Navitas, which is a shareholding subsidiary of Saipu Instruments, which is mainly engaged in the separation and purification of macromolecules, announced that it will increase its capital by 10 million yuan to Saipu Instruments, holding a total of 32.
70% of the equity
of the subsidiary after the capital increase.
It is reported that Saipu Instrument has achieved a cumulative market installed capacity of nearly 1,000 units, and there are many customers who have repeatedly purchased, which belongs to the domestic head brand
in the field of laboratory protein purification.
News on October 29, Changsha in the fourth quarter of major projects concentrated on the start of the event, the main venue of the activity set up in the Chutian science and technology polymer material industrial park construction site
.
It is reported that the industrial park is the R & D and production base of Chutian Microsphere Biotechnology (Changsha) Co.
, Ltd.
, a holding subsidiary of Chutian Technology, which will build 11 monomers such as microsphere workshop, R&D building and experimental building, mainly used for the production of chromatography microsphere products for the separation and purification of biological macromolecules, and the project is constructed
in two phases.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.